These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 3735530)

  • 41. 17-year follow-up of a randomized prospective controlled trial of adjuvant intravesical doxorubicin in the treatment of superficial bladder cancer.
    Cheng CW; Chan PS; Chan LW; Chan CK; Ng CF; Lai MM
    Int Braz J Urol; 2005; 31(3):204-11. PubMed ID: 15992422
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Prevention of recurrence in non-invasive bladder carcinoma. Experiences with 400 patients].
    Burk K; Troller RM; Pittner P
    Urologe A; 1983 Sep; 22 Suppl():332-6. PubMed ID: 6356556
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-term mitomycin C instillation after transurethral resection of superficial bladder carcinoma: influence on recurrence, progression and survival.
    Huland H; Otto U; Droese M; Klöppel G
    J Urol; 1984 Jul; 132(1):27-9. PubMed ID: 6427483
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A cocktail regimen of intravesical mitomycin-C, doxorubicin, and cisplatin (MDP) for non-muscle-invasive bladder cancer.
    Chen CH; Yang HJ; Shun CT; Huang CY; Huang KH; Yu HJ; Pu YS
    Urol Oncol; 2012; 30(4):421-7. PubMed ID: 20870427
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy.
    Herr HW
    J Urol; 2005 Dec; 174(6):2134-7. PubMed ID: 16280743
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup.
    Solsona E; Iborra I; Ricós JV; Monrós JL; Casanova J; Dumont R
    J Urol; 1999 Apr; 161(4):1120-3. PubMed ID: 10081851
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of principles in intravesical chemo- and immunotherapy for superficial bladder cancer.
    Jauhiainen K; Rintala E; Kaasinen E; Ruutu M; Alfthan O
    Arch Esp Urol; 1990; 43 Suppl 2():159-64. PubMed ID: 2129004
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Combination chemotherapy of mitomycin C and cytosine arabinoside in the intravesical treatment for superficial bladder tumors: report 2. Evaluation of prophylactic intravesical infusion therapy].
    Ikeuchi T; Onodera Y; Kai Y
    Gan To Kagaku Ryoho; 1984 Apr; 11(4):858-63. PubMed ID: 6426397
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European Organization for Research and Treatment of Cancer Genitourinary Group.
    Bouffioux C; Kurth KH; Bono A; Oosterlinck W; Kruger CB; De Pauw M; Sylvester R
    J Urol; 1995 Mar; 153(3 Pt 2):934-41. PubMed ID: 7853578
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Influence of thiotepa and doxorubicin instillation at time of transurethral surgical treatment of bladder cancer on tumor recurrence: a prospective, randomized, double-blind, controlled trial.
    Zincke H; Utz DC; Taylor WF; Myers RP; Leary FJ
    J Urol; 1983 Mar; 129(3):505-9. PubMed ID: 6403716
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Combined intracavitary and external beam irradiation for superficial transitional cell carcinoma of the bladder: an alternative to cystectomy for patients with recurrence after intravesical chemotherapy.
    Russell KJ; Koh WJ; Russell AH; Griffin BR; Markette KL; Tong DY; Griffin TW
    J Urol; 1989 Jan; 141(1):30-2. PubMed ID: 2491760
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Intravesial instillation of recombination interferon-alpha and pirarubicin in the prophylaxis of local recurrence after resection of the superficial bladder cancer].
    Deng JH; Bai JL; Zhang SS; Ma PC; Wan JH
    Ai Zheng; 2004 Jul; 23(7):839-41. PubMed ID: 15248924
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations.
    Lebret T; Bohin D; Kassardjian Z; Herve JM; Molinie V; Barre P; Lugagne PM; Botto H
    J Urol; 2000 Jan; 163(1):63-7. PubMed ID: 10604315
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Cases of the regression of advanced bladder tumors (T2-T4) after the use of chemotherapy].
    Kumanov Kh; Ormanov I; Tsvetkov M; Donovski L; Panchev P
    Khirurgiia (Sofiia); 1990; 43(1):87-93. PubMed ID: 2395293
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intravesical 4'-epi-doxorubicin (epirubicin) versus bacillus Calmette-Guérin. A controlled prospective study on the prophylaxis of superficial bladder cancer.
    Melekos MD; Chionis HS; Paranychianakis GS; Dauaher HH
    Cancer; 1993 Sep; 72(5):1749-55. PubMed ID: 8348504
    [TBL] [Abstract][Full Text] [Related]  

  • 56. First-line chemotherapy of superficial bladder cancer: mitomycin vs thiotepa.
    Heney NM
    Urology; 1985 Oct; 26(4 Suppl):27-9. PubMed ID: 3931325
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Local mitomycin-C therapy of infiltrating bladder cancer].
    Erdmann WD; Harzmann R; Flüchter SH; Bichler KH
    Fortschr Med; 1984 Aug; 102(29-30):767-71. PubMed ID: 6437950
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Is there an optimal treatment scheme for adjuvant intravesical therapy? Preliminary analysis of an EORTC protocol comparing early and delayed instillation with and without maintenance of either adriamycin or mitomycin-C in patients with superficial transitional carcinoma of the bladder.
    Kurth KH; Bouffioux C; Sylvester R; de Pauw M
    Prog Clin Biol Res; 1988; 269():525-37. PubMed ID: 3134663
    [No Abstract]   [Full Text] [Related]  

  • 59. Stage T1, grade 3 transitional cell carcinoma of the bladder: an unfavorable tumor?
    Jakse G; Loidl W; Seeber G; Hofstädter F
    J Urol; 1987 Jan; 137(1):39-43. PubMed ID: 3795364
    [TBL] [Abstract][Full Text] [Related]  

  • 60. BCG-(RIVM) versus mitomycin intravesical therapy in patients with superficial bladder cancer. EORTC GU Group and the Dutch South-East Collaborative Group.
    Debruyne FM; van der Meijden AP; Franssen MP
    Prog Clin Biol Res; 1989; 303():435-46. PubMed ID: 2506556
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.